Review Article

Complex Regional Pain Syndrome Classification, Damage, Mechanisms, and Treatment: A Narrative Review

Seyed Majid Haghighat-Shoar[1], Mehrdad Mokaram Dori[2]*, Azita Farzaneh[3]

[1]Department of Anesthesiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

[2]Department of Anesthesiology and Pain Medicine, Emam Reza Hospital, Mashhad University of medical Science, Mashhad, Iran.

[3]Department of Pediatric, Shahid Beheshti University of Medical Science, Tehran, Iran.

ARTICLE INFO

ABSTRACT

Complex regional pain syndrome (CRPS), previously known as reflex sympathetic dystrophy syndrome, is a situation specified by persistent regional pain. The aberrant functioning of the neurological system is believed to be the root cause of an exaggerated reactivity to pain signals that are unable to switch off the sensation of pain. It is characterized by such symptoms as swelling, alterations in the color of the skin and tissues, along with edema. Although it most commonly affects the limbs, such as the arm, leg, hand, or foot, these symptoms can manifest themselves in any part of the body. The existence or nonexistence of nerve injury is used to classify patients into one of two subgroups, I or II, when referring to this illness. Since many medical professionals are unfamiliar with the diagnosis of CRPS and its etiology is not fully elucidated, the condition is frequently incorrectly diagnosed. The treatments available for CRPS focus on alleviating symptoms, regaining organ function, and cosseting a person's quality of life, despite the fact that no cure for the condition has been identified.

Introduction

Complex regional pain syndrome (CRPS) is an uncommon clinical situation identified by persistent regional pain (not in a particular dermatome) that is excessive in intensity and duration compared to the underlying cause. It is typically along with sensorimotor, vasomotor, sudomotor, and trophic changes in the affected site [1-2]. This pain is usually more intense or long-lasting than typical after similar tissue traumas, especially in the distal extremity [3]. Symptoms are localized to the affected limb but may spread to other areas [4]. This disorder was first described by Ambroise Paré, the father of modern surgery, almost 465 years ago, in 1557. An acute and constant pain syndrome happened to the French King Charles IX of Valois after limb phlebotomy and was successfully relieved [5-6].

It is proven that notable autonomic and inflammatory changes in the site of pain distinguish CRPS from other chronic pain conditions (Pain lasting longer than three months is considered chronic [7]). This condition manifests as extreme hyperalgesia and allodynia in the limbs (ordinarily non-painful stimuli, like touch and cold, are perceived as painful), changes in skin color, temperature, and sweating in comparison with the noninvolved side, edema, altered patterns of hair, skin, or nail growth in the affected areas, decreased strength, tremors, and dystonia [8]. It is worth noting that scientists arranged CRPS as type I or type II based on the absence or presence of clinical signs of peripheral nerve injury [3].

There is an urgent need for early and aggressive therapeutic interventions, in addition to comprehensive

The authors declare no conflicts of interest.
*Corresponding author.
E-mail address: mokarramdm@mums.ac.ir

diagnostic evaluation [9]. Although CRPS was explained decades ago, its epidemiology has not yet been well surveyed, and compelling epidemiological data on this abnormality are still missing, along with meager incidence statistics [10]. Nonetheless, between 5.5 and 26.2 per 100,000 person-years have been reported as the incidence of CRPS, and women are reported to be more frequently affected than men [11]. Furthermore, based on the literature, the course of CRPS and its prognosis are exceedingly unpredictable. Only approximately 5% of symptoms resolve [12], although they frequently become much better over the course of the first year, and many people have continuing CRPS with considerable functional impairment and low quality of life [13-14].

In order to find a suitable treatment for these patients, researchers suggested pain alleviation as one of the main aim of CRPS treatment, which is followed by an increase in the patient's overall satisfaction with life. Physiotherapy and cognitive behavioral therapy (CBT) are also part of the treatment plan [15]. Moreover, the trophic alterations of the afflicted extremity are hypothesized to be influenced by catecholamines and autoimmune processes [16]. They mainly stimulate nociceptors of deep tissues, resulting in motion-associated pain. Some of these mediators also activate second-order neurons in the spinal cord, which are in charge of deep tissue or skin mechanical hyperalgesia. If CRPS is not properly managed during this inflammatory stage, susceptible patients experience cortical remodeling over time due to the constant input of nociceptive activity to the brain [17]. Due to the importance of this disease among neurologists and pain specialists, the current survey discusses the characteristics, treatment methods, and mechanisms of pain transmission.

Clinical criteria in patients with CRPS

The CRPS patients exhibit various clinical features in different stages of the disease. To confirm the diagnosis of this syndrome, there must be a certain number of symptoms described below. Researchers refer to these diagnostic criteria as Budapest criteria [18].

1)   There is continuous pain in the patient, often disproportionate to the cause of the pain.

2)   At least one symptom from three of the four categories below must be reported by the patient:

a. Sensory manifestations: The patient mentions allodynia or hyperesthesia.

b. Vasomotor symptoms include temperature asymmetry, skin color variations, and/or color asymmetry, according to the patient.

c. Motor or trophic symptoms: The patient reports a reduced range of motion and/or motor dysfunction, such as weakness, tremor, dystonia, and/or trophic modifications in hair, nails, and skin.

d. Sudomotor or edema manifestations: The patient describes edema, sweating abnormalities, and/or sweating asymmetry.

3)   At least one indication in two or more of the four categories listed below

a. Sensory symptoms, such as hyperalgesia to pinpricks, allodynia to light touches, or stiffness in the joints

b. Vasomotor symptoms, such as asymmetry in skin color or temperature

c. Motor or trophic symptoms: reduced movement range and/or muscle weakness, tremor, dystonia, and/or trophic changes of hair, nails, and skin.

d. Sudomotor or edema signs: edema and/or sweating asymmetry

4)   No alternative explanation for the symptoms and indications is more accurate [19-20].

Nevertheless, it is noteworthy that it is not yet apparent how or to what extent any of these pathways contribute to the development and maintenance of this disease [11].

Type of complex regional pain syndrome

There are different subtypes and/or stages of CRPS, and the phenomena are not consistent among individuals [18]. For example, in 1994, at a conference organized by the International Association for the Study of Pain (IASP), the "officially approved" term "complex regional pain syndrome" was coined to describe the disease in general. The disease was later classified into "CRPS 2" in the presence of nerve damage (replacing the term causalgia) and "CRPS 1" if there was no evidence of nerve damage (replacing the term reflex sympathetic dystrophy) [21]. Based on previously conducted studies, despite a low frequency, CRPS 1 imposes s heavy burden on patients and is associated with significant direct medical and social expenditures (such as lost productivity, disability, and social security payments) [14, 16, 22] Nevertheless, one-third of CRPS 1 patients will not respond to treatment and will instead develop a long-term condition with severe pain, disability, and diminished quality of life [22]. Chronic CRPS 1 is more likely to develop if proper diagnosis and therapy are delayed; however, early treatment is associated with better outcomes [16].

There is another different classification with two distinct subtypes: "warm" and "cold," the former of which is linked to acute inflammation, and the latter is primarily present in chronic CRPS [23]. Patients with warm CRPS demonstrate an extremity that is warm, red, dry, and edematous, while cold CRPS patients are characterized by an extremity that is cold, blue, sweating, and less edematous. In accordance with clinical data, the mean CRPS duration was significantly shorter in the warm CRPS subtype (4.7 months) compared to that in the cold CRPS subtype (20 months), with similar pain intensity in both subtypes [23].

Mechanisms involved in the development of complex regional pain syndrome

As expected, several underlying mechanisms are involved in the forming and persistence of this disease, leading to the development of pathological conditions in the patient. The pathophysiology of CRPS has long been associated with peripheral neurogenic inflammation [24]. Studies have pointed to several molecular mechanisms in the creation of these conditions. For instance, uncontrolled blood sugar can make CRPS after stroke more common [25]. Even in cold CRPS, inflammatory mechanisms appear to be crucial [26]. Direct evidence has been presented regarding decreased tissue oxygen saturation [27]. and autoantibody-mediated autoimmune processes [28]. Increased amounts of proteobacteria and lower amounts of firmicutes in the gut microbiome have been hypothesized as autoimmune mechanisms through which the gut microbiome may contribute to CRPS [29].

Primary afferent sensory neurons release neuropeptides during peripheral neurogenic inflammation, leading to cutaneous vasodilation (primarily via substance P [S.P.]), changes in vascular permeability (primarily via calcitonin gene-related peptide [CGRP]), increased protein efflux, and improved leukocyte recruitment [30, 31]. Therefore, the symptoms of CRPS patients, including allodynia, hyperalgesia, edema, vasodilation, and trophic abnormalities, may also be resulted from this elevated neuropeptide release [32, 33]. In addition to neurogenic inflammation, some other surveys have given Evidence regarding the role of neuroinflammation (i.e., glial cell activation leading to increased production of proinflammatory cytokines and chemokines) in CRPS [34-36].

Apart from being brought on by different types of trauma and surgery, primary afferent nerve fibers and/or higher-order neurons have also been theorized to have a role in neuroinflammation [36, 37]. A change from acute to chronic pain and the maintenance of chronic pain are just two negative consequences of Neuroinflammation. Central cytokines, chemokines, and mediators released by glia are what cause and maintain the central sensitization that leads to this chronic pain [36]. Clinical manifestations of dynamic tactile allodynia, secondary punctate and/or pressure hyperalgesia, temporal summation, and pain after touching are all signs of central sensitization, which is specified by pain hypersensitivity [38].

Central sensitization symptoms reported in CRPS patients [11] have been linked to the sensitization of the nociceptive system as a result of chronic pain and, thus, continuous nociceptive input [39, 40]. In addition, it is noteworthy that for a long period, the disruption of the immune system was not considered a probable pathophysiological mechanism in CRPS since there was no objective evidence, such as C-reactive protein and white blood cells that are generally within the normal range in these patients, pointing to immune system involvement [41-43]. Nonetheless, in recent years, substantial advances in study methodologies and Knowledge of the disease have made it possible to pinpoint the function of the immune system in CRPS.

There is growing evidence that dysregulated immune activation and consequent inflammation have a duty to play in CRPS, including the enhancement of the levels of Tumor necrosis factor (TNF-α), the incidence of different autoantibodies, and T lymphocyte activation [11]. Increased serum concentration of neuropeptides [43-45], mast cell tryptase, and interleukin (IL)-6 (also in cerebrospinal fluid) have also been determined, while anti-inflammatory cytokines have been discovered to be decreased [46].

Changes in brain structure and function in patients with complex regional pain syndrome

Researchers have pointed to significant alterations in brain structure and function in CRPS; nonetheless, these changes may occur before or during the disease. For more explanation, neuroimaging studies demonstrating decreased gray matter (GM) volume and cortical thickness in the prefrontal cortex (PFC), insular cortex (IC), and basal ganglia provided Evidence of brain plasticity [47]. The anterior IC and orbitofrontal cortex showed CRPS-specific GM volume reductions when collated to other chronic pain disorders [48]. Clearly, CRPS is frequently attributed to pain processing and is connected to functional connectivity alterations in the default mode network (DMN) [49-50].

Several investigations have explained a reduction in GM volume/density in the anterior IC and areas of the PFC; although, it is not known whether these structural and functional brain changes emerge quickly after diagnosis or gradually over time. This is related to the length of CRPS and the pain severity; therefore, it is suggested that professionals think of it as a series of minor slow changes that decrease with the patient's pain intensity [51-52]. Moreover, it has been discovered that contralateral thalamic perfusion is increased within the first year of disease but comes back to normal levels for prolonged illness durations [52-53]. Therefore, understanding the variations in the brain across CRPS stages may help explain the variety of therapy responses.

Clinical diagnosis methods of complex regional pain syndrome

The updated International Association for the Study of Pain (IASP) clinical diagnostic criteria for CRPS are presently used to identify the condition [1]. Both primary care physicians and hospital specialists tend to miss the diagnosis of CRPS. The consequences include a delay in

the identification of CRPS cases and initiation of effective treatment. The noteworthy point is that long-term CRPS-related pain becomes more difficult to manage without effective treatment [54]. Therefore, the detection of CRPS is still a challenge in daily clinical practice due to the wide range of clinical symptoms [55] This disease may be accompanied by other diseases or have symptoms similar to other diseases.

Nonetheless, only other disorders, like rheumatic diseases, are excluded from the differential diagnosis by further testing, like blood tests and radiography [56]. The average time between injury and CRPS diagnosis ranged from 0.5-10 years, according to a study [57]. When the diagnosis is postponed, treatment effectiveness suffers even more. Some researchers have proposed the use of bone scintigraphy (BS) to confirm the detection of CRPS 1, even though this diagnosis is based on the Budapest criteria [58]. It is not known if the percentage of positive BS results is affected by patient variables [55]. Furthermore, a meta-analysis looked at the sensitivity and specificity of both BS and magnetic resonance imaging (MRI) for the detection of CRPS 1 [59].

Methods

It is generally stated that CRPS is an incurable pain disorder without any specific therapeutic strategy; therefore, it requires a multimodal treatment strategy [18]. In a study on three patients who touch the Budapest criteria for CRPS, Thor used perineural injection therapy as a treatment to reduce their pain [60]. One of the most recent developments in the field of regenerative medicine is perineural injection treatment (PIT) which targets cutaneous nerves as a potential source of pain [61-62]. Moreover, sympathetic blocks are a well-known technique for the reduction of pain and enhancement of motor and autonomic nervous system activities [63].

In this method, in individuals with CRPS in their lower extremities, a nerve block with local anesthetics is typically performed on the lumbar sympathetic chain. The blocking effects in most patients are transient; therefore, one or more of the further procedures, such as repeated sympathetic blocks with local anesthetics, radiofrequency thermocoagulation, or neurodestructive procedures using alcohol or phenol, are required to exert a more lasting effect [64]. For instance, botulinum toxin can block the sympathetic ganglion and inhibit acetylcholine release at cholinergic nerve endings via the antagonistic effect of botulinum toxin [65].

Literature is filled with studies reporting the Use of different clinical treatments for CRPS; however, the level of protective evidence is largely inadequate for most [66]. Bisphosphonates, for example, have been proposed as a treatment for CRPS-related pain. Furthermore, dimethyl sulfoxide, steroids, epidural clonidine, intrathecal

baclofen, spinal cord stimulation, and motor imagery programs have demonstrated pain relief, although additional research is needed [67]. Anticonvulsants and antidepressants, which are often administered by specialists and thought to help with sensory-associated symptoms in CRPS, have not created clear effects, according to a review of the research [67-68]. In addition, anticonvulsants, such as gabapentin, are widely used to treat neuropathic pain and CRPS 1; although, it is not well established whether anticonvulsants or antidepressants, included due to similarity in mechanism, are helpful in the relief of CRPS-related pain [69-70]. It should be mentioned that physical therapy is advised for CRPS patients by American, U.K., and more recent Dutch recommendations [20,69]. The U.K. guidelines specifically suggest education as another therapeutic pillar [20].

Conclusions

In general, the observations obtained from various studies have pointed out that there is still no definitive and effective treatment method for CRPS patients. Considering numerus physical, psychological, and social problems posed to the affected patients, it is suggested that more clinical studies be conducted to find a suitable and unified treatment method.

References

[1] Harden RN, Bruehl S, Perez RS, Birklein F, Marinus J, Maihofner C, et al. Validation of proposed diagnostic criteria (the "Budapest Criteria") for complex regional pain syndrome. Pain. 2010; 150(2):268-74.

[2] Iolascon G, Tarantino U. Rare diseases in orthopedics: algodystrophy and aseptic osteonecrosis. Clin Cases Miner Bone Metab. 2015; 12(Suppl 1):2.

[3] Bruehl S. Complex regional pain syndrome. Bmj. 2015; 351.

[4] van Rijn MA, Marinus J, Putter H, Bosselaar SR, Moseley GL, van Hilten JJ. Spreading of complex regional pain syndrome: not a random process. J Neural Transm (Vienna). 2011; 118(9):1301-9.

[5] Iolascon G, de Sire A, Moretti A, Gimigliano F. Complex regional pain syndrome (CRPS) type I: historical perspective and critical issues. Clin Cases Miner Bone Metab. 2015; 12(Suppl 1):4.

[6] Michael d'A SH. CRPS: what's in a name? Taxonomy, epidemiology, neurologic, immune and autoimmune considerations. Reg Anesth Pain Med. 2019; 44(3):376-87.

[7] Barke A, Korwisi B, Jakob R, Konstanjsek N, Rief W, Treede RD. Classification of chronic pain for the International Classification of Diseases (ICD-11): results of the 2017 international World Health

Organization field testing. Pain. 2022; 163(2):e310.

[8] Harden RN, Bruehl S, Galer BS, Saltz S, Bertram M, Backonja M, et al. Complex regional pain syndrome: are the IASP diagnostic criteria valid and sufficiently comprehensive?. Pain. 1999; 83(2):211-9.

[9] Pappagallo M, Rosenberg AD. Epidemiology, pathophysiology, and management of complex regional pain syndrome. Pain Practice. 2001; 1(1):11-20.

[10] Ratti C, Nordio A, Resmini G, Murena L. Post-traumatic complex regional pain syndrome: clinical features and epidemiology. Clin Cases Miner Bone Metab. 2015; 12(Suppl 1):11.

[11] Bharwani KD, Dik WA, Dirckx M, Huygen FJ. Highlighting the role of biomarkers of inflammation in the diagnosis and management of complex regional pain syndrome. Mol Diagn Ther. 2019; 23(5):615-26.

[12] Bean DJ, Johnson MH, Heiss-Dunlop W, Kydd RR. Extent of recovery in the first 12 months of complex regional pain syndrome type-1: A prospective study. Eur J Pain. 2016; 20(6):884-94.

[13] Bean DJ, Johnson MH, Kydd RR. The outcome of complex regional pain syndrome type 1: a systematic review. J Pain. 2014; 15(7):677-90.

[14] Schwartzman RJ, Erwin KL, Alexander GM. The natural history of complex regional pain syndrome. Clin J Pain. 2009 May 1;25(4):273-80.

[15] Weissmann R, Uziel Y. Pediatric complex regional pain syndrome: a review. Pediatr Rheumatol Online J. 2016; 14(1):1-0.

[16] Birklein F, O'Neill D, Schlereth T. Complex regional pain syndrome: an optimistic perspective. Neurology. 2015; 84(1):89-96.

[17] Van Velzen GA, Rombouts SA, Van Buchem MA, Marinus J, Van Hilten JJ. Is the brain of complex regional pain syndrome patients truly different?. European Journal of Pain. 2016; 20(10):1622-33.

[18] Harden RN, Oaklander AL, Burton AW, Perez RS, Richardson K, Swan M, et al. Complex regional pain syndrome: practical diagnostic and treatment guidelines. Pain Med. 2013; 14(2):180-229.

[19] Birklein F, Schlereth T. Complex regional pain syndrome—significant progress in understanding. Pain. 2015; 156:S94-103.

[20] Goebel A, Turner-Stokes LF. Complex regional pain syndrome in adults: UK guidelines for diagnosis, referral and management in primary and secondary care.2018.

[21] Stanton-Hicks M, Jänig W, Hassenbusch SA, Haddox JD, Boas R, Wilson P. Reflex sympathetic dystrophy: changing concepts and taxonomy. Pain. 1995; 63(1):127-33.

[22] Duman I, Dincer U, Taskaynatan MA, Cakar E, Tugcu I, Dincer K. Reflex sympathetic dystrophy: a retrospective epidemiological study of 168 patients. Clin Rheumatol. 2007; 26(9):1433-7.

[23] Bruehl S, Maihöfner C, Stanton-Hicks M, Perez RS, Vatine JJ, Brunner F, et al. Complex regional pain syndrome: evidence for warm and cold subtypes in a large prospective clinical sample. Pain. 2016; 157(8):1674-81.

[24] Birklein F, Schmelz M. Neuropeptides, neurogenic inflammation and complex regional pain syndrome (CRPS). Neuroscience letters. 2008; 437(3):199-202.

[25] Choi JH, Yu KP, Yoon YS, Kim ES, Jeon JH. Relationship between HbA1c and complex regional pain syndrome in stroke patients with type 2 diabetes mellitus. Ann Rehabil Med. 2016; 40(5):779-85.

[26] Dirckx M, Stronks DL, VAN BODEGRAVEN-HOF EA, Wesseldijk F, Groeneweg JG, Huygen FJ. Inflammation in cold complex regional pain syndrome. Acta Anaesthesiol Scand. 2015; 59(6):733-9.

[27] Bellingham GA, Smith RS, Morley-Forster P, Murkin JM. Use of near infrared spectroscopy to detect impaired tissue oxygen saturation in patients with complex regional pain syndrome type 1. Can J Anaesth. 2014; 61(6):563-70.

[28] Goebel A, Blaes F. Complex regional pain syndrome, prototype of a novel kind of autoimmune disease. Autoimmun Rev. 2013; 12(6):682-6.

[29] Reichenberger ER, Alexander GM, Perreault MJ, Russell JA, Schwartzman RJ, Hershberg U, et al. Establishing a relationship between bacteria in the human gut and complex regional pain syndrome. Brain Behav Immun. 2013; 29:62-9.

[30] Hall JM, Brain SD. Pharmacology of calcitonin gene-related peptide. Neurogenic inflammation. Boca Raton: CRC Press LLC. 1996; 101-4.

[31] Holzer P. Neurogenic vasodilatation and plasma leakage in the skin. General Pharmacology: The Vascular System. 1998; 30(1):5-11.

[32] Weber M, Birklein F, Neundörfer B, Schmelz M. Facilitated neurogenic inflammation in complex regional pain syndrome. Pain. 2001; 91(3):251-7.

[33] Littlejohn G. Neurogenic neuroinflammation in fibromyalgia and complex regional pain syndrome. Nat Rev Rheumatol. 2015; 11(11):639-48.

[34] Jeon SY, Seo S, Lee JS, Choi SH, Lee DH, Jung YH, et al. [11C]-(R)-PK11195 positron emission tomography in patients with complex regional pain syndrome: A pilot study. Medicine. 2017; 96(1):e5735.

[35] Jung YH, Kim H, Jeon SY, Kwon JM, Lee WJ, Kim YC, et al. Brain metabolites and peripheral biomarkers associated with neuroinflammation in complex regional pain syndrome using [11C]-(R)-PK11195 positron emission tomography and magnetic resonance spectroscopy: a pilot study. Pain Medicine. 2019; 20(3):504-14.

[36] Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and central sensitization in chronic and widespread pain. Anesthesiology. 2018; 129(2):343-66.

[37] Xanthos DN, Sandkühler J. Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity. Nature Reviews

Neuroscience. 2014; 15(1):43-53.

[38] Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. pain. 2011; 152(3):S2-15.

[39] Reimer M, Rempe T, Diedrichs C, Baron R, Gierthmühlen J. Sensitization of the nociceptive system in complex regional pain syndrome. PLoS One. 2016; 11(5):e0154553.

[40] Bruehl S. An update on the pathophysiology of complex regional pain syndrome. Anesthesiology. 2010; 113(3):713-25.

[41] Veldman PH, Reynen HM, Arntz IE, Goris RJ. Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients. The Lancet. 1993; 342(8878):1012-6.

[42] Ribbers GM, Oosterhuis WP, van Limbeek J, de Metz M. Reflex sympathetic dystrophy: is the immune system involved?. Arch Phys Med Rehabil. 1998; 79(12):1549-52.

[43] Schinkel C, Gaertner A, Zaspel J, Zedler S, Faist E, Schuermann M. Inflammatory mediators are altered in the acute phase of posttraumatic complex regional pain syndrome. Clin J Pain. 2006; 22(3):235-9.

[44] Blair SJ, Chinthagada M, Hoppenstehdt D, Kijowski R, Fareed J. Role of neuropeptides in pathogenesis of reflex sympathetic dystrophy. Acta Orthop Belg. 1998; 64(4):448-51.

[45] Birklein F, Schmelz M, Schifter SA, Weber M. The important role of neuropeptides in complex regional pain syndrome. Neurology. 2001; 57(12):2179-84.

[46] König S, Schlereth T, Birklein F. Molecular signature of complex regional pain syndrome (CRPS) and its analysis. Expert Rev Proteomics. 2017; 14(10):857-67.

[47] Shokouhi M, Clarke C, Morley-Forster P, Moulin DE, Davis KD, Lawrence KS. Structural and functional brain changes at early and late stages of complex regional pain syndrome. J Pain. 2018; 19(2):146-57.

[48] Baliki MN, Schnitzer TJ, Bauer WR, Apkarian AV. Brain morphological signatures for chronic pain. PloS one. 2011; 6(10):e26010.

[49] Baliki MN, Mansour AR, Baria AT, Apkarian AV. Functional reorganization of the default mode network across chronic pain conditions. PloS one. 2014; 9(9):e106133.

[50] Becerra L, Sava S, Simons LE, Drosos AM, Sethna N, Berde C, et al. Intrinsic brain networks normalize with treatment in pediatric complex regional pain syndrome. NeuroImage: Clinical. 2014; 6:347-69.

[51] Barad MJ, Ueno T, Younger J, Chatterjee N, Mackey S. Complex regional pain syndrome is associated with structural abnormalities in pain-related regions of the human brain. J Pain. 2014; 15(2):197-203.

[52] Geha PY, Baliki MN, Harden RN, Bauer WR, Parrish TB, Apkarian AV. The brain in chronic CRPS pain: abnormal gray-white matter interactions in emotional and autonomic regions. Neuron. 2008; 60(4):570-81.

[53] Fukumoto M, Ushida T, Zinchuk VS, Yamamoto H, Yoshida S. Contralateral thalamic perfusion in patients with reflex sympathetic dystrophy syndrome. The Lancet. 1999; 354(9192):1790-1.

[54] Breivik H, Stubhaug A. Importance of early diagnosis of complex regional pain syndrome (CRPS-1 and CRPS-2): Delayed diagnosis of CRPS is a major problem. Scand J Pain. 2016; 11(1):49-51.

[55] Wertli MM, Brunner F, Steurer J, Held U. Usefulness of bone scintigraphy for the diagnosis of Complex Regional Pain Syndrome 1: A systematic review and Bayesian meta-analysis. PloS one. 2017; 12(3):e0173688.

[56] Van Zundert J, Patijn J, Hartrick C, Lataster A, Huygen F, Mekhail N, et al. Evidence-based interventional pain medicine: according to clinical diagnoses. Pain Pract. 2011; 11(5):423-9.

[57] Lunden LK, Kleggetveit IP, Jørum E. Delayed diagnosis and worsening of pain following orthopedic surgery in patients with complex regional pain syndrome (CRPS). Scand J Pain. 2016;11(1):27-33.

[58] Harden RN, Bruehl S, Stanton-Hicks M, Wilson PR. Proposed new diagnostic criteria for complex regional pain syndrome. Pain medicine. 2007; 8(4):326-31.

[59] Cappello ZJ, Kasdan ML, Louis DS. Meta-analysis of imaging techniques for the diagnosis of complex regional pain syndrome type I. J Hand Surg Am. 2012; 37(2):288-96.

[60] Thor JA, Mohamed Hanapi NH, Halil H, Suhaimi A. Perineural injection therapy in the management of complex regional pain syndrome: a sweet solution to pain. Pain Medicine. 2017; 18(10):2041-5.

[61] Reeves KD, Lyftogt J. Prolotherapy: regenerative injection therapy. Pain Management. Philadelphia, PA, Elsevier. 2007 Jan 1:1106-27.

[62] Geppetti P, Holzer P. Neurogenic inflammation. Crc Press; 1996.

[63] Sharma A, Williams K, Raja SN. Advances in treatment of complex regional pain syndrome: recent insights on a perplexing disease. Curr Opin Anaesthesiol. 2006; 19(5):566-72.

[64] Kim WO, Yoon KB, Kil HK, Yoon DM. Chemical lumbar sympathetic block in the treatment of plantar hyperhidrosis: a study of 69 patients. Dermatol Surg. 2008; 34(10):1340-5.

[65] Chen S. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins. 2012; 4(10):913-39.

[66] Javed S, Abdi S. Use of anticonvulsants and antidepressants for treatment of complex regional pain syndrome: a literature review. Pain Management. 2021; 11(2):189-99.

[67] Tran DQ, Duong S, Bertini P, Finlayson RJ. Treatment of complex regional pain syndrome: a review of the evidence. Can J Anaesth. 2010; 57(2):149-66.

[68] Perez RS, Zollinger PE, Dijkstra PU, Thomassen-Hilgersom IL, Zuurmond WW, Rosenbrand KC, et al.

Evidence based guidelines for complex regional pain syndrome type 1. BMC neurology. 2010; 10(1):1-4.

[69] Mackey S, Feinberg S. Pharmacologic therapies for complex regional pain syndrome. Curr Pain Headache Rep. 2007; 11(1):38-43.

[70] Harke H, Gretenkort P, Ladleif HU, Rahman S, Harke O. The response of neuropathic pain and pain in complex regional pain syndrome I to carbamazepine and sustained-release morphine in patients pretreated with spinal cord stimulation: a double-blinded randomized study. The response of neuropathic pain and pain in complex regional pain syndrome I to carbamazepine and sustained-release morphine in patients pretreated with spinal cord stimulation: a double-blinded randomized study. 2001; 92(2):488-95.